Stockreport

Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer [Yahoo! Finance]

Lantheus Holdings, Inc.  (LNTH) 
Last lantheus holdings, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.lantheus.com/investor-relations
PDF PYLCLARI ® (INN: Piflufolastat ( F) also known as ( F)-DCFPyL, is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron [Read more]